Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: Is it safe?

Mohseni-Bod, Hadi; MacRae, Duncan; Slavík, Zdeněk

doi:10.1097/01.pcc.0000123552.36127.22

Cited by 55 publications

(49 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[6,7] Our patient was given a lower dose of octreotide than what was reported in the literature and developed NEC on 4th day of treatment which is in accordance to the published literature. We associated the NEC findings to the octreotide treatment since it appeared within 90 hours the treatment was initiated and subsided quickly (48 hours) after the treatment was discontinued.…”

Section: Discussionsupporting

confidence: 72%

Necrotizing Enterocolitis after Octreotide Treatment in a Preterm Newborn with Idiopathic Congenital Chylothorax

et al. 2017

View full text Add to dashboard Cite

Octreotide, a somatostatin analogue, has been used for the management of patients with refractory chylothorax. Side effects related to the gastrointestinal system associated with octreotide are necrotizing enterocolitis (NEC) and focal intestinal perforation. NEC is the most common and dangerous gastrointestinal emergency in premature infants. We present the development of necrotizing enterocolitis after octreotide treatment in a preterm infant with idiopathic congenital chylothorax which settled after discontinuation of octreotide.

show abstract

Section: Discussionsupporting

confidence: 72%

Necrotizing Enterocolitis after Octreotide Treatment in a Preterm Newborn with Idiopathic Congenital Chylothorax

et al. 2017

View full text Add to dashboard Cite

show abstract

“…17 The present patient had an acute clinical presentation, likely because of the large amount of chyle drained by the thoracic duct. 5 The frequency of mortality associated with chylothorax has reached approximately 10% in major medical centers.…”

Section: Discussionmentioning

confidence: 99%

“…Malignancies, either lymphoma (nonHodgkin lymphoma, 60%) or other malignancies (lung carcinoma), cause > 50% nontraumatic occurrences of chylothorax. [3][4][5][6]9,10 Right heart failure with venous hypertension can cause chylothorax. 11,12 Central venous thrombosis and chylothorax may occur in the absence of the usual risk factors-either hereditary thrombophilia or acquired thromboembolic factors-in a patient with septic shock, and procoagulant states such as those induced by sepsis may contribute to the development of chylothorax.…”

Section: Discussionmentioning

confidence: 99%

“…In pseudochylothorax-developed with chronic empyema-the cholesterol level is > 200 mg/dL, no chylomicrons are present, and cholesterol crystals are noted on microscopy. [3][4][5][6] Chylothorax usually is caused by a thoracic duct leak and is suspected in patients with milky effusions and in the presence of specific comorbidities or a history of chest or neck trauma. Transudative chylothorax has been reported when cirrhosis, nephrosis, or heart failure is present.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Untitled

2014

Exp Clin Transplant

View full text Add to dashboard Cite

Chylothorax is the accumulation of chyle in the pleural cavity as a result of damage to the lymphatic ducts. We treated a young man who was a kidney transplant recipient who had a prior internal jugular vein permanent catheter for hemodialysis, who developed dyspnea and hypoxemia. Chest radiography showed bilateral pleural effusion. Analysis of the white, milky, cloudy, odorless effusion fluid showed cell count > 500/μL; lymphocytes, 60%; total protein, 3.6 mg/dL; urea nitrogen, 45 mg/dL; creatinine, 90 μmol/L; triglycerides, above 2.2 mmol/L (repeatedly high); lactate dehydrogenase, 450 U/L (normal); and cultures, no growth. Magnetic resonance imaging showed thrombosis of the major neck veins, superior vena cava, and azygos vein. Treatment included pleural drains, gut rest, and dietary modification, octreotide, and warfarin. The chylothorax resolved with no relapse. In summary, chylothorax may occur in patients associated with thrombosis of major veins associated with a permanent dialysis catheter.

show abstract

“…117,118 The optimal timing of introduction and duration of treatment is unknown. 2 Side effects of somatostatin and octreotide include hyperglycemia, hypothyroidism, 119 cramps, nausea, diarrhea, renal impairment, necrotizing enterocolitis, 120 and liver dysfunction. 115,116 A case of anaphylaxis has been reported in a child after the use of octreotide.…”

Section: Figurementioning

confidence: 99%

Chylothorax in Infants and Children

2014

View full text Add to dashboard Cite

Chylothorax, the accumulation of chyle in the pleural space, is a relatively rare cause of pleural effusion in children. It can cause significant respiratory morbidity, as well as lead to malnutrition and immunodeficiency. Thus, a chylothorax requires timely diagnosis and treatment. This review will first discuss the anatomy and physiology of the lymphatic system and discuss various causes that can lead to development of a chylothorax in infants and children. Then, methods of diagnosis and treatment will be reviewed. Finally, complications of chylothorax will be reviewed. Pediatrics 2014;133:722-733

show abstract

Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: Is it safe?

Abstract: We report the association of postoperative chylothorax treated with somatostatin analog (octreotide) and necrotizing enterocolitis in an infant following aortic coarctation repair.

Cited by 55 publications

References 9 publications

Necrotizing Enterocolitis after Octreotide Treatment in a Preterm Newborn with Idiopathic Congenital Chylothorax

Necrotizing Enterocolitis after Octreotide Treatment in a Preterm Newborn with Idiopathic Congenital Chylothorax

Untitled

Chylothorax in Infants and Children

Contact Info

Product

Resources

About